Buys | $83,159 | 3 | 25 |
Sells | $488,749 | 9 | 75 |
Rock Edwin | Chief Medical Officer | 2 | $78,825 | 0 | $0 | $78,825 |
Hahn Brian M. | SVP Finance, CFO | 1 | $4,335 | 0 | $0 | $4,335 |
Invus Public Equities, L.P. | 10 percent owner | 0 | $0 | 9 | $488,749 | $-488,749 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect …
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.17M and sold $2.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
2024-08-08 | Sale | Invus Public Equities, L.P. | 10 percent owner | 260,873 0.4135% | $0.19 | $50,009 | +34.59% | |
2024-08-07 | Sale | Invus Public Equities, L.P. | 10 percent owner | 61,488 0.0996% | $0.18 | $11,197 | +44.72% | |
2024-08-06 | Sale | Invus Public Equities, L.P. | 10 percent owner | 55,732 0.0882% | $0.18 | $10,188 | +40.79% | |
2024-08-05 | Sale | Invus Public Equities, L.P. | 10 percent owner | 164,523 0.2612% | $0.19 | $30,996 | +36.99% | |
2024-08-02 | Sale | Invus Public Equities, L.P. | 10 percent owner | 286,200 0.4383% | $0.20 | $57,354 | +24.24% | |
2024-08-01 | Sale | Invus Public Equities, L.P. | 10 percent owner | 63,564 0.0987% | $0.22 | $13,743 | +16.76% | |
2024-07-30 | Sale | Invus Public Equities, L.P. | 10 percent owner | 756,835 1.1897% | $0.22 | $167,185 | +15.18% | |
2024-07-29 | Sale | Invus Public Equities, L.P. | 10 percent owner | 363,949 0.5697% | $0.24 | $85,637 | +7.63% | |
2024-07-26 | Sale | Invus Public Equities, L.P. | 10 percent owner | 258,335 0.4016% | $0.24 | $62,440 | +4.02% | |
2024-06-21 | Rock Edwin | Chief Medical Officer | 115,000 0.1787% | $0.27 | $30,717 | +0.47% | ||
2024-06-20 | Rock Edwin | Chief Medical Officer | 190,000 0.2799% | $0.25 | $48,108 | +3.16% | ||
2024-06-18 | Hahn Brian M. | SVP Finance, CFO | 17,500 0.0252% | $0.25 | $4,335 | +6.32% | ||
2023-09-22 | Rock Edwin | Chief Medical Officer | 30,403 0.0463% | $1.38 | $41,956 | -0.71% | ||
2023-09-21 | Rock Edwin | Chief Medical Officer | 35,000 0.0544% | $1.38 | $48,300 | +2.17% | ||
2023-05-17 | Sale | Hahn Brian M. | SVP Finance, CFO | 3,700 0.0059% | $1.95 | $7,215 | -15.69% | |
2023-05-10 | JUNIUS DANIEL M | director | 30,000 0.0441% | $1.56 | $46,800 | -1.14% | ||
2023-05-08 | Johnson Bruce S | SVP & Chief Commercial Officer | 13,500 0.0237% | $1.57 | $21,195 | +18.24% | ||
2023-02-24 | Invus Public Equities, L.P. | 10 percent owner | 100,000 0.1667% | $1.70 | $170,000 | -5.03% | ||
2023-02-23 | Invus Public Equities, L.P. | 10 percent owner | 200,000 0.3399% | $1.75 | $350,760 | -5.85% | ||
2023-02-22 | Invus Public Equities, L.P. | 10 percent owner | 150,000 0.2504% | $1.79 | $268,995 | -9.55% |
Invus Public Equities, L.P. | 10 percent owner | 6317565 9.7926% | $1.64M | 8 | 9 | <0.0001% |
Rock Edwin | Chief Medical Officer | 680403 1.0547% | $176,632.62 | 7 | 0 | <0.0001% |
Hahn Brian M. | SVP Finance, CFO | 70643 0.1095% | $18,338.92 | 2 | 3 | +31.85% |
BVF PARTNERS L P/IL | 10 percent owner | 4980812 7.7205% | $1.29M | 3 | 0 | <0.0001% |
BARRIS PETER J | 10 percent owner | 4702791 7.2896% | $1.22M | 1 | 2 | <0.0001% |
$992,222,850 | 90 | -12.52% | $19.11M | |
$8,900,811 | 57 | -24.79% | $14.9M | |
$6,204,522 | 45 | 1.91% | $18.93M | |
GlycoMimetics, Inc. (GLYC) | $85,897,100 | 36 | 2.47% | $16.75M |
$217,684 | 34 | 1.61% | $17.84M |
Increased Positions | 22 | +47.83% | 16M | +91.35% |
Decreased Positions | 16 | -34.78% | 4M | -20.74% |
New Positions | 16 | New | 16M | New |
Sold Out Positions | 11 | Sold Out | 3M | Sold Out |
Total Postitions | 52 | +13.04% | 30M | +70.62% |
Bvf Inc/Il | $2,596.00 | 14.68% | 9.54M | 0 | 0% | 2024-12-31 |
Logos Global Management Lp | $1,469.00 | 8.31% | 5.4M | +5M | New | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $1,385.00 | 7.83% | 5.09M | +5M | New | 2024-12-31 |
Vr Adviser, Llc | $816.00 | 4.62% | 3M | +3M | New | 2024-12-31 |
Vanguard Group Inc | $726.00 | 4.11% | 2.67M | 0 | 0% | 2024-12-31 |
Wellington Management Group Llp | $384.00 | 2.17% | 1.41M | +1M | New | 2024-12-31 |
Blackrock, Inc. | $198.00 | 1.12% | 728,637 | +779 | +0.11% | 2024-12-31 |
Geode Capital Management, Llc | $142.00 | 0.8% | 521,223 | 0 | 0% | 2024-12-31 |
Jefferies Financial Group Inc. | $115.00 | 0.65% | 423,777 | +423,777 | New | 2024-12-31 |
Adar1 Capital Management, Llc | $90.00 | 0.51% | 331,827 | +286,127 | +626.1% | 2024-12-31 |